McIntyre R, Berk M, Brietzke E, Goldstein B, López-Jaramillo C, Kessing L, et al. Bipolar disorders. Lancet. 2020;396:1841–56.
Article CAS PubMed Google Scholar
Craddock N, Sklar P. Genetics of bipolar disorder. Lancet. 2013;381:1654–62.
Article CAS PubMed Google Scholar
Ludwig B, Dwivedi Y. Dissecting bipolar disorder complexity through epigenomic approach. Mol psychiatry. 2016;21:1490–8.
Article CAS PubMed PubMed Central Google Scholar
Lan M, McLoughlin G, Griffin J, Tsang T, Huang J, Yuan P, et al. Metabonomic analysis identifies molecular changes associated with the pathophysiology and drug treatment of bipolar disorder. Mol psychiatry. 2009;14:269–79.
Article CAS PubMed Google Scholar
Wang Y, Sun K, Liu Z, Chen G, Jia Y, Zhong S, et al. Classification of unmedicated bipolar disorder using whole-brain functional activity and connectivity: a radiomics analysis. Cereb cortex. 2020;30:1117–28.
Drago A, Crisafulli C, Calabrò M, Serretti A. Enrichment pathway analysis. The inflammatory genetic background in Bipolar Disorder. J Affect Disord. 2015;179:88–94.
Fernandes B, Steiner J, Molendijk M, Dodd S, Nardin P, Gonçalves C, et al. C-reactive protein concentrations across the mood spectrum in bipolar disorder: a systematic review and meta-analysis. Lancet Psychiatry. 2016;3:1147–56.
Wu W, Zheng YL, Tian LP, Lai JB, Hu CC, Zhang P, et al. Circulating T lymphocyte subsets, cytokines, and immune checkpoint inhibitors in patients with bipolar II or major depression: a preliminary study. Sci Rep. 2017;7:40530.
Article CAS PubMed PubMed Central Google Scholar
Barbosa I, Rocha N, Assis F, Vieira É, Soares J, Bauer M, et al. Monocyte and lymphocyte activation in bipolar disorder: a new piece in the puzzle of immune dysfunction in mood disorders. Int J Neuropsychopharmacol. 2014;18:021.
Berk M, Kapczinski F, Andreazza A, Dean O, Giorlando F, Maes M, et al. Pathways underlying neuroprogression in bipolar disorder: focus on inflammation, oxidative stress and neurotrophic factors. Neurosci Biobehav Rev. 2011;35:804–17.
Article CAS PubMed Google Scholar
Morais L, Schreiber H, Mazmanian S. The gut microbiota-brain axis in behaviour and brain disorders. Nat Rev Microbiol. 2021;19:241–55.
Article CAS PubMed Google Scholar
Long-Smith C, O’Riordan KJ, Clarke G, Stanton C, Dinan TG, Cryan JF. Microbiota-gut-brain axis: new therapeutic opportunities. Annu Rev Pharmacol Toxicol. 2020;60:477–502.
Article CAS PubMed Google Scholar
Rios A, Maurya P, Pedrini M, Zeni-Graiff M, Asevedo E, Mansur R, et al. Microbiota abnormalities and the therapeutic potential of probiotics in the treatment of mood disorders. Rev Neurosci. 2017;28:739–49.
Abildgaard A, Elfving B, Hokland M, Wegener G, Lund S. Probiotic treatment reduces depressive-like behaviour in rats independently of diet. Psychoneuroendocrinology. 2017;79:40–8.
Article CAS PubMed Google Scholar
Desbonnet L, Garrett L, Clarke G, Kiely B, Cryan J, Dinan T. Effects of the probiotic Bifidobacterium infantis in the maternal separation model of depression. Neuroscience. 2010;170:1179–88.
Article CAS PubMed Google Scholar
Zheng P, Zeng B, Zhou C, Liu M, Fang Z, Xu X, et al. Gut microbiome remodeling induces depressive-like behaviors through a pathway mediated by the host’s metabolism. Mol Psychiatry. 2016;21:786–96.
Article CAS PubMed Google Scholar
Huang T, Lai J, Du Y, Xu Y, Ruan L, Hu S. Current Understanding of gut microbiota in mood disorders: an update of human studies. Front Genet. 2019;10:98.
Article CAS PubMed PubMed Central Google Scholar
Borre Y, O’Keeffe G, Clarke G, Stanton C, Dinan T, Cryan J. Microbiota and neurodevelopmental windows: implications for brain disorders. Trends Mol Med. 2014;20:509–18.
Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, et al. The Mini-International Neuropsychiatric Interview (MINI): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1998; 59(Suppl 20): 22–33;quiz 34–57.
Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134:382–9.
Article CAS PubMed Google Scholar
Young RC, Biggs JT, Ziegler VE, Meyer DA. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry. 1978;133:429–35.
Article CAS PubMed Google Scholar
Bajaj J, Hylemon P, Ridlon J, Heuman D, Daita K, White M, et al. Colonic mucosal microbiome differs from stool microbiome in cirrhosis and hepatic encephalopathy and is linked to cognition and inflammation. Am J Physiol Gastrointest Liver Physiol. 2010;303:675–85.
Tana C, Umesaki Y, Imaoka A, Handa T, Kanazawa M, Fukudo S. Altered profiles of intestinal microbiota and organic acids may be the origin of symptoms in irritable bowel syndrome. Neurogastroenterol Motil. 2010;22(512–519):e114-515.
Matera G, Muto V, Vinci M, Zicca E, Abdollahi-Roodsaz S, van de Veerdonk F, et al. Receptor recognition of and immune intracellular pathways for Veillonella parvula lipopolysaccharide. Clin Vaccine Immunol. 2009;16:1804–9.
Article CAS PubMed PubMed Central Google Scholar
Evans SJ, Bassis CM, Hein R, Assari S, Flowers SA, Kelly MB, et al. The gut microbiome composition associates with bipolar disorder and illness severity. J Psychiatr Res. 2017;87:23–9.
Jiang H, Ling Z, Zhang Y, Mao H, Ma Z, Yin Y, et al. Altered fecal microbiota composition in patients with major depressive disorder. Brain Behav Immun. 2015;48:186–94.
Quévrain E, Maubert M, Michon C, Chain F, Marquant R, Tailhades J, et al. Identification of an anti-inflammatory protein from Faecalibacterium prausnitzii, a commensal bacterium deficient in Crohn’s disease. Gut. 2016;65:415–25.
Tanca A, Abbondio M, Palomba A, Fraumene C, Manghina V, Cucca F, et al. Potential and active functions in the gut microbiota of a healthy human cohort. Microbiome. 2017;5(1):79.
Article PubMed PubMed Central Google Scholar
Leonel A, Alvarez-Leite J. Butyrate: implications for intestinal function. Curr Opin Clin Nutr Metab Care. 2012;15:474–9.
Article CAS PubMed Google Scholar
Yamawaki Y, Fuchikami M, Morinobu S, Segawa M, Matsumoto T, Yamawaki S. Antidepressant-like effect of sodium butyrate (HDAC inhibitor) and its molecular mechanism of action in the rat hippocampus. World J Biol Psychiatry. 2012;13:458–67.
Wei Y, Melas P, Wegener G, Mathé A, Lavebratt C. Antidepressant-like effect of sodium butyrate is associated with an increase in TET1 and in 5-hydroxymethylation levels in the Bdnf gene. Int J Neuropsychopharmacol. 2014;18:1.
Vital M, Howe A, Tiedje J. Revealing the bacterial butyrate synthesis pathways by analyzing (meta)genomic data. MBio. 2014;5:00889.
Fernández J, Redondo-Blanco S, Gutiérrez-del-Río I, Miguélez EM, Villar CJ, Lombó F. Colon microbiota fermentation of dietary prebiotics towards short-chain fatty acids and their roles as anti-inflammatory and antitumour agents: a review. J Funct Foods. 2016;25:511–22.
Colpo G, Leboyer M, Dantzer R, Trivedi M, Teixeira A. Immune-based strategies for mood disorders: facts and challenges. Expert Rev Neurother. 2018;18:139–52.
Article CAS PubMed Google Scholar
Painold A, Mörkl S, Kashofer K, Halwachs B, Dalkner N, Bengesser S, et al. A step ahead: Exploring the gut microbiota in inpatients with bipolar disorder during a depressive episode. Bipolar disord. 2019;21:40–9.
Article CAS PubMed Google Scholar
Crapser J, Ritzel R, Verma R, Venna V, Liu F, Chauhan A, et al. Ischemic stroke induces gut permeability and enhances bacterial translocation leading to sepsis in aged mice. Aging. 2016;8:1049–63.
Article CAS PubMed PubMed Central Google Scholar
Looft T, Levine U, Stanton T. Cloacibacillus porcorum sp. nov., a mucin-degrading bacterium from the swine intestinal tract and emended description of the genus Cloacibacillus. Int J Syst Evol Microbiol. 2013;63:1960–6.
Article CAS PubMed PubMed Central Google Scholar
Bailey M, Dowd S, Galley J, Hufnagle A, Allen R, Lyte M. Exposure to a social stressor alters the structure of the intestinal microbiota: implications for stressor-induced immunomodulation. Brain Behav Immun. 2011;25:397–407.
Article CAS PubMed Google Scholar
Kverka M, Zakostelska Z, Klimesova K, Sokol D, Hudcovic T, Hrncir T, et al. Oral administration of Parabacteroides distasonis antigens attenuates experimental murine colitis through modulation of immunity and microbiota composition. Clin Exp Immunol. 2011;163:250–9.
Comments (0)